Novel Bifunctional Compounds Targeting Nicotine and Dopamine Receptor Subtypes: Synthesis and Pharmacological Investigation

Future therapies for diseases associated with altered dopaminergic signaling, including Parkinson\u2019s disease, schizophrenia and drug addiction or drug dependence, may be substantially built on the existence of intramembrane receptor-receptor interactions within receptor mosaics where it is believed that the D2 receptor may operate as the \u201chub receptor\u201d [1]. In particular, it has been proposed that striatal dopaminergic neurotransmission could be under the control of receptor heteromers containing D2 autoreceptors and non-alpha7 nicotinic acetylcholine heteroreceptors [2]. In an attempt to investigate the biochemical and functional interactions between dopaminergic autoreceptors and nAChRs containing the beta2 subunit, we designed and prepared a group of potential bifunctional derivatives incorporating a D2/D3 agonist moiety and a nicotinic alpha4beta2 antagonist fragment, linked by polymethylene spacers of different length. The new compounds have been biologically characterized for their affinity/specificity/functional profile at the target nACh and D2 receptor subtypes. The synthesis of the designed derivatives and the results of their pharmacological investigation will be presented and discussed. [1] K.Fuxe, D.Marcellino, A.Rivera, Z.Diaz-Cabiale, M.Filip, B.Gago, D.C.S.Roberts, U.Langel, S.Genedani, L.Ferraro, A.de la Calle, J.Narvaez, S.Tanganelli, A.Woods, L.F.Agnati, Brain Res.Rev., 58, 2008, 415-452. [2] D.Quarta, F.Ciruela, K.Patkar, J.Borycz, M.Solinas, C.Lluis, R.Franco, R.A.Wise, S.R.Goldberg, B.T.Hope, A.Woods, S.Ferr\ue9, Neuropsychopharmacol., 32, 2007, 35-42

Synthesis of a group of novel Xanomeline/77-LH-28-1 hybrid ligands and their FRET investigation at muscarinic acetylcholine receptor subtypes

In connection with our interest in investigating novel rationally designed bitopic (i.e., orthosteric/allosteric) derivatives targeting muscarinic acetylcholine receptor (mAChR) subtypes (1,2,3), in this study we designed and synthesized a new set of ligands that integrate in the same molecular skeleton the pharmacophoric moieties of Xanomeline and of 77-LH-28-1 (1-[3-(4-butyl-1-piperidinyl)propyl]-3,4-dihydro-2(1H)-quinolinone). Xanomeline is a well-known M1/M4-preferring orthosteric agonist, which ameliorated cognitive impairments in Alzheimer\u2019s disease patients and showed activity in various models of schizophrenia, thus being potentially beneficial for treatment of positive, negative and cognitive symptoms (4). On the other hand, 77-LH-28-1 was characterized as an M1-selective, positive allosteric modulator, thus representing an interesting pharmacological tool with cognition enhancing properties (5). As illustrated below, we planned the novel bipharmacophoric derivatives as merged structures, with the tetrahydropyridine nucleus of Xanomeline as the central core. In the last years, different receptor sensors, based on the fluorescence resonance energy transfer (FRET), were generated for various G protein-coupled receptors, and represented a valuable tool to investigate real time receptor activation as well as ligand-receptor interactions. Recently, this analysis was performed also on a set of bitopic ligands designed for a selective interaction with M1 mAChRs (6). Our preliminary results on the group of Xanomeline/77-LH-28-1 hybrid compounds indicate, for the M1 sensor, a reproducible activation response, which depends on the linker length. Conversely, no FRET-related effect could be detected at the M2 sensor. Thus, a critical spacer length of the hybrid compounds induces conformational changes with a degree of selectively for the M1 muscarinic receptor. The synthesis and the results of pharmacological investigation will be presented and discussed. References: 1. J. Antony, K. Kellershohn, M. Mohr-Andr\ue4, A. Kebig, S. Prilla, M. Muth, E. Heller, T. Disingrini, C. Dallanoce et al., FASEB J 2009, 23, 442-450. 2. A. Bock, B. Chirinda, F. Krebs, R. Messerer, J. B\ue4tz, M. Muth, C. Dallanoce et al., Nat. Chem. Biol. 2014, 10, 18-20. 3. A. Bock, M. Bermudez, F. Krebs, C. Matera, B. Chirinda, D. Sydow, C. Dallanoce et al., J. Biol. Chem. 2016, 291, 16375-16389. 4. S. Barak, I. Weiner, Int. J. Neuropsychoph. 2011, 14, 1233-1246. 5. C. J. Langmead, N. E. Austin, C. L. Branch, J. T. Brown, K. A. Buchanan, C. H. Davies, I. T. Forbes et al., Br. J. Pharmacol. 2008, 154, 1104-1115. 6. R. Messerer, M. Kauk, D. Volpato, M. C. Alonso Canizal, J. Kl\uf6ckner, U. Zabel, S. Nuber, C. Hoffmann, U. Holzgrabe, ACS Chem. Biol. 2017, 12, 833-843

Synthesis of novel epibatidine-related derivatives through 1,3-dipolar cycloaddition of pyridinenitrile oxides

n/

Peptide derivatives and therapeutic activity thereof

Disclosed are peptide or pseudopeptide derivatives containing a nitrogenous heterocyclic residue with blocking activity against the by-products of lipid oxidative, stress, and in particular of unsaturated aldehydes such as malondialdehyde and 4-hydroxy-trans-2-nonenal (HNE). Formula (I

Synthesis and application of isotope-labeled carnosine in LCMS/MS

Carnosine is an endogenous dipeptide, composed of \u3b2-alanine and L-histidine, and is highly concentrated in skeletal muscle and other excitable tissues. Its physiological roles, based on its biochemical properties, include pH-buffering, metal-ion chelation and antioxidant capacity as well as the ability to protect against the formation of advanced glycation and lipoxidation end-products.1 For these reasons, besides its nutritional ergogenic application in the sport community,2 carnosine supplementation offers a therapeutic potential for the treatment of numerous diseases in which ischemic or oxidative stress is involved.1 Quantitation of carnosine in biological matrices appears to be crucial for these applications, and LC-MS procedures with isotope-labeled internal standards are the state-of-the-art approach for this analytical need.3 The use of these standards allows to account for variations during the complex sample preparation process, different matrix effects between patient samples, and variations in instrument performance. Figure 1 In this work, we present a fast and highly efficient synthetic route to obtain a deuterated carnosine analogue (Figure 1) starting from the trideuterated L-histidine (\u3b1-d1, imidazole-2,5-d2). Moreover, the use of Carnosine-d3 in the validation of a multiple reaction monitoring (MRM) LC-MS/MS method for the analytical quantitation of carnosine in a biological matrix will be reported. References 1. Boldyrev, A. A.; Aldini, G.; Derave, W. Physiol. Rev. 2013, 93, 1803\u20131845. 2. Brisola, G.; Zagatto, A. J. Strength Cond. Res. 2019, 33, 253-282. 3. Stokvis, E.; Rosing, H.; L\uf3pez-L\ue1zaro, L.; Schellens, J. H. M.; Beijnen, J. H. Biomed. Chromatogr. 2004, 18, 400-402

Effects mediated by the α7 nicotinic acetylcholine receptor on cell proliferation and migration in rat adipose-derived stem cells

Adipose-derived stem cells (ASCs) are an attractive source for regenerative medicine as they can be easily iso-lated, rapidly expandable in culture and show excellent in vitro differentiation potential. Acetylcholine (ACh), one of the main neurotransmitters in central and peripheral nervous systems, plays key roles in the control of several physiological processes also in non-neural tissues. As demonstrated in our previous studies, ACh can contribute to the rat ASCs physiology, negatively modulating ASCs proliferation and migration via M2 mus-carinic receptor (mAChR) activation. In the present work we show that rat ASCs also express α7 nicotinic receptors (nAChRs). In particular, we have investigated the effects mediated by the selective activation of α7 nAChRs, which causes a reduction of ASC proliferation without affecting cell survival and morphology, and significantly promotes cell migration via upregulation of the CXCR4 expression. Interestingly, the activation of the α7 nAChR also upregulates the expression of M2 mAChR protein, indicating a cooperation between muscarinic and nicotinic receptors in the inhibition of ASC proliferation

Design and synthesis of selective ligands targeting different nAChR subtypes

Differences in the pharmacological and functional properties of the nicotinic acetylcholine receptors (nAChRs) largely depend on their subunit composition. Recent studies indicate that receptor subtypes are selectively implicated in some diseases in which nAChRs have been found to be modi\ufb01ed. In order to control different nicotinic brain functions pharmacologically, it is very important to have drugs (agonists or antagonists) that selectively affect the different receptor subtypes in such a way as to maximize the desired effect and minimize the unwanted effects. To achieve these goals, we designed and synthesized different series of compounds potentially able to selectively activate nAChR subtypes (alpha3beta4 and alpha7)

Design, synthesis and preliminary biological evaluation of 3-cyclopropyl-4-phenoxy-1H-pyrazole derivatives as small molecular ligands of RAGE

Receptor for advanced glycation end products (RAGE) is a multiligand receptor belonging to the immunoglobulin superfamily and plays a crucial role in the development of many human diseases such as neurodegenerative diseases, diabetes, cardiovascular diseases and cancer.1 RAGE is involved in a number of cell processes such as neuroinflammation, apoptosis, proliferation and autophagy, and therefore it is of considerable interest as a promising drug target for innovative therapeutic approaches. It consists of an extracellular region, a short hydrophobic transmembrane spanning region, and a highly charged amino acid cytoplasmatic tail. The extracellular region contains a signal peptide, followed by one N-terminal V-type immunoglobulin domain and two C-type (C1 and C2) immunoglobulin domains.2 RAGE is able to interact with a large number of pro-inflammatory and regulatory molecules, such as advanced glycation end-products (AGEs), quinolinic acid, beta amyloid (A\u3b2), high mobility group box 1 (HMGB1), S100/calgranulin family proteins.3,4 However, due to the structural heterogeneity of these endogenous ligands, little is known about the key pharmacophore elements for ligand-RAGE interaction and the specific mode of binding. On these grounds, we aimed at designing new small molecules able to bind the VC1 extracellular domains of RAGE, in order to clarify the structural features that account for RAGE affinity and activation, and to identify new drug-like compounds. Following a process of structural simplification of known pyrazole-5-carboxamide RAGE ligands,1 we planned a set of novel derivatives characterized by a variously functionalized 3-cyclopropyl-4-phenoxy-1H-pyrazole scaffold (Figure 1). The design and synthesis of the new putative RAGE ligands will be presented and discussed, together with the results of their in vitro screening by means of a surface plasmon resonance (SPR)-based assay to estimate their binding ability to the RAGE extracellular domain. References 1. Bongarzone S., Savickas V., Luzi F., Gee A. D. J. Med. Chem. 2017, 60, 7213-7232. 2. Hudson B. I., Carter A. M., Harja E., Kalea A. Z., Arriero M., Yang H., Grant P. J., Schmidt A. M. FASEB J. 2008, 22, 1572-1580. 3. Xue J., Rai V., Singer D., Chabierski S., Xie J., Reverdatto S., Burz D. S., Schmidt A. M., Hoffmann R., Shekhtman A. Structure 2011, 19, 722\u2013732. 4. Koch M., Chitayat S., Dattilo B. M., Schiefner A., Diez J., Chazin W. J., Fritz, G. Structure 2010, 18, 1342-1352

Muscarinic dualsteric ligands behave as partial or protean agonists depending on the affinity of their orthosteric moiety

Muscarinic acetylcholine receptors have been extensively studied with the purpose of finding selective ligands for their modulation. In the last years, a new strategy was developed towards this aim, i.e. the synthesis of so-called dualsteric ligands that bind simultaneously to both the orthosteric and the allosteric site of the M2 receptor.Two dualsteric compounds, Iper-6-naph and Isox- 6-naph, and their orthosteric fragments were studied in GTP\u3b3S assays and [3H]NMS binding studies, performed with membranes of CHO cells expressing the human M2 receptor. The experiments were carried out in Tris buffer supplemented with either 2 mM or 200 mM NaCl, in order to have the receptor in its spontaneously active or inactive conformations, respectively. In both buffers, Iper-6-naph was a partial agonist and it almost completely abolished [3H]NMS binding. In contrast, Isox-6-naph revealed a protean nature, behaving either as inverse or partial agonist, respectively, in 2 mM and 200 mM NaCl, and it promoted [3H] NMS binding. Since the two hybrid compounds share the same allosteric moiety, these discrepancies have to be attributed to pharmacological differences of the orthosteric moieties, whose potencies and affinities were indeed reported to be significantly divergent. In conclusion, this study suggests that slight structural modifications in the orthosteric building block of dualsteric ligands may cause a reversal of ligand efficacy and, most importantly, it provides a deeper insight into the molecular determinants of protean agonism at the M2 receptor

Novel pharmacological tools which activate mAChRs: a question of "dualsterism"

Muscarinic acetylcholine receptors (mAChRs) represent an excellent model system to study orthosteric and allosteric interactions. The high sequence homology shown by orthosteric sites of mAChRs has hampered the development of subtype selective agonists. On the other hand, allosteric recognition sites are less conserved among the various mAChR subtypes. We synthesized a series of hybrid ligands designed to simultaneously interact with both orthosteric and allosteric sites (\u201cdualsteric\u201d compounds) by fusing orthosteric activators with M2-selective allosteric fragments (W84 and Naphmethonium). In particular, among the oxotremorine-like orthosteric agents, iperoxo emerged as a potent agonist with supraphysiological efficacy but devoid of subtype selectivity.1 To explore the whole chemical space of the binding region, we modified the structure of the three component parts (orthosteric and allosteric moieties and spacer) of dualsteric ligands.2 These ligands permitted to prove for the first time that GPCR\u2019s allosteric vestibule is able to control the extent of receptor movement to govern a hierarchical order of G-protein coupling.3 In addition, they were found to dynamically switch between two distinct binding orientations, engendering both active and inactive populations of receptors bound by a given ligand.4 More recently, some of these ligands (notably N-8-IPER) revealed interesting antinociceptive properties and good tolerability.5 The synthetic approaches together with relevant results and implications of the biological investigation will be presented. References 1. Schrage R et al. Agonists with supraphysiological efficacy at the muscarinic M2 ACh receptor. Br J Pharmacol 2013;169(2):357-70. 2. Disingrini T et al. Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors. J Med Chem 2006;49(1):366-72; Antony J et al. Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity. FASEB J 2009;23(2):442-50. 3. Bock A et al. The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling. Nat Commun 2012;3:1044. 4. Bock A et al. Dynamic ligand binding dictates partial agonism at a G protein-coupled receptor. Nat Chem Biol 2014;10(1):18-20. 5. Matera C et al. Bis(ammonio)alkane-type agonists of muscarinic acetylcholine receptors: Synthesis, in vitro functional characterization, and in vivo evaluation of their analgesic activity. Eur J Med Chem 2014;75:222-232